Please find the session links next to their corresponding agenda item.
Thursday, March 17
11:00 AM
FDLI Welcome and Announcements
Khara L. Minter, Assistant Director, Training Programs, FDLI
Enter this session: https://fdli.zoom.us/j/83326367730
11:05 AM– 12:20 PM
Biosimilar Biological Products
Michelle Divelbiss, Associate, Covington & Burling LLP
Enter this session: https://fdli.zoom.us/j/83326367730
12:20 – 12:30 PM
Break
12:30 – 1:15 PM
Post-Approval Pharmacovigilance
Abeba Habtemariam, Counsel, Arnold & Porter LLP
Enter this session: https://fdli.zoom.us/j/83574882702
1:15 – 1:25 PM
Break
1:25 – 2:25 PM
Regulation of Biological Manufacturing
Neil Di Spirito, Partner, Brown Rudnick LLP
Enter this session: https://fdli.zoom.us/j/85611793888
2:25 – 2:35 PM
Break
2:35 – 3:35 PM
Regulation of Biological Product Marketing
Sarah Blankstein, Associate, Ropes & Gray LLP
Enter this session: https://fdli.zoom.us/j/88599592476
3:35 – 3:45 PM
Break
3:45 – 5:00 PM
Violations, Enforcement, and International Issues
Brian J. Malkin, Partner,McDermott Will & Emery
Enter this session: https://fdli.zoom.us/j/89489487983
5:00 PM
Adjournment
An access link will be provided to attendees via email upon registration.
If you are registering on behalf of someone else, the link to access the webinar will go to the email address provided at the point of registration.
Those registering on the day of the webinar will receive an access link via email upon successful payment.
We use Zoom to conduct webinars which works on most devices. You may participate in the webinar on a mobile device via the Zoom App or by dialing in. If you require the dial in information, please contact Coleen Carney at [email protected].
Test your device: https://support.zoom.us/hc/en-us/articles/201362193-Joining-a-meeting
Webinar recordings are sent via email as soon as we are able to process and verify the quality of the recording. This usually occurs within 3 business days of a webinar broadcast.
If multiple people at your organization wish to participate from separate devices, each will be required to purchase access.